Medicines regulator not planning to suspend J&J shot after US flags risk of rare neurological condition
Guillain-Barre syndrome is a disorder in which the body’s immune system attacks the nervous system, causing muscle weakness and potential paralysis
14 July 2021 - 20:23
SA’s medicines regulator says it does not anticipate suspending use of the Johnson & Johnson (J&J) coronavirus vaccine after US authorities warned earlier this week of a possible association with a rare neurological condition called Guillain-Barre syndrome.
The J&J shot is one of two vaccines being administered in the national coronavirus inoculation drive and is central to the government’s plans to reach 70% of the adult population by March 2022...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.